2. Signaling Pathways
  3. TGF-beta/Smad
  4. TGF-β Receptor
  5. GDF15 Isoform

GDF15

GDF15 is a stress-inducible secreted member of the transforming growth factor-β superfamily, originally described as macrophage inhibitory cytokine-1 and later characterized as a liver-injury–induced growth differentiation factor[1][2]. In metabolic and inflammatory stress, GDF15 functions as an endocrine signal that links peripheral tissue injury, nutrient stress, and systemic adaptation rather than acting as a conventional intracellular signaling enzyme[3][4]. Mechanistically, circulating GDF15 engages the hindbrain GFRAL–RET pathway, which controls food intake, body weight, and energy balance, making the GDF15–GFRAL axis a central experimental model for anorexia, cachexia, nausea, and obesity research[4][5]. In disease models, GDF15 supports tissue tolerance during infection and inflammatory injury, while human pregnancy studies link fetal and maternal GDF15 biology to nausea and hyperemesis gravidarum risk[3][6]. Compared with related GDF/TGF-β family ligands, the selected literature distinguishes GDF15 by its divergent sequence identity, stress-responsive expression, and GFRAL-dependent endocrine biology rather than by functionally validated GDF15 isoforms[1][2][4]. For experimental applications, recombinant GDF15 or metformin-induced GDF15 elevation can model pathway activation, whereas anti-GDF15 antibody blockade, including ponsegromab, tests causal involvement in cancer cachexia and appetite-loss phenotypes[5][7].

GDF15 Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-P99241
    Ponsegromab
    		Inhibitor 99.60%
    Ponsegromab is a Growth differentiation factor 15 (GDF15) inhibitor with human, cynomolgus monkey, and mouse target IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM, respectively. Ponsegromab acts as a chemosensitizer, increases intracellular reactive oxygen species, reduces glutathione levels. Ponsegromab can be used for the research of oxaliplatin-resistant colorectal cancer.
  • HY-W587486
    N-Acetyltaurine
    		Inhibitor 99.91%
    N‑acetyltaurine is an orally active endogenous sulfonate that is synthesized from taurine and acetate in the renal cortex. N‑acetyltaurine supports bacterial growth as a sole fixed nitrogen or carbon source. N‑acetyltaurine buffers acetyl moieties of mitochondrial acetyl‑CoA in skeletal muscle. N‑acetyltaurine reduces food intake and body weight in obese and lean wild‑type mice in a GFRAL‑dependent manner. N‑acetyltaurine can be used for the research of diet‑induced obesity, hyperacetatemia and diabetes.
  • HY-P99100
    Visugromab
    		Inhibitor 98.40%
    Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
  • HY-P991190
    Rilogrotug
    		Inhibitor 99.9%
    Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15.
  • HY-149406
    AMPK activator 12
    		Activator 99.68%
    AMPK activator 12 (compound 21) is a potent AMPK activator and GDF15 inducer. AMPK activator 12 increases GDF15 protein levels in human hepatic cells.
  • HY-183332
    YXX0248
    		Activator
    YXX0248 is an orally active anti-hypoxic agent. YXX0248 upregulates mRNA expression of FGF21 and GDF15 via activation of the ISR/ATF4 transcriptional axis. YXX0248 exhibits low cytotoxicity. YXX0248 enhances hypoxic survival in mice. YXX0248 can be used for the research of acute mountain sickness and hypoxia-related diseases.
  • HY-183331
    YXX0237
    		Activator
    YXX0237 is an orally active anti-hypoxic agent. YXX0237 upregulates mRNA expression of FGF21 and GDF15 via activation of the ISR/ATF4 transcriptional axis. YXX0237 exhibits low cytotoxicity. YXX0237 enhances hypoxic survival in mice. YXX0237 can be used for the research of acute mountain sickness and hypoxia-related diseases.
  • HY-RS16542
    Gdf15 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Gdf15 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gdf15 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS05352
    GDF15 Human Pre-designed siRNA Set A
    		Inhibitor

    GDF15 Human Pre-designed siRNA Set A contains three designed siRNAs for GDF15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-P99100A
    Visugromab (Powder)
    		Inhibitor
    Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
  • HY-RS22974
    Gdf15 Rat Pre-designed siRNA Set A
    		Inhibitor

    Gdf15 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gdf15 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-W587486A
    N-Acetyltaurine hemimagnesium
    		Inhibitor
    N-Acetyltaurine hemimagnesium is an orally active endogenous sulfonate that is synthesized from taurine and acetate in the renal cortex. N-Acetyltaurine hemimagnesium supports bacterial growth as a sole fixed nitrogen or carbon source. N-Acetyltaurine hemimagnesium buffers acetyl moieties of mitochondrial acetyl‑CoA in skeletal muscle. N-Acetyltaurine hemimagnesium reduces food intake and body weight in obese and lean wild‑type mice in a GFRAL‑dependent manner. N-Acetyltaurine hemimagnesium can be used for the research of diet‑induced obesity, hyperacetatemia and diabetes.